Fresenius Medical Care (FMS)

• Market cap: $15.2B
• 1 day: -0.88%
• 5 days: -5.12%
• 1 month: -9.28%
• 3 months: 2.13%
• 6 months: 3.93%
• Year to date: 17.02%
• 1 year: 32.04%
• 5 years: -41.21%
• 10 years: -36.84%
• Sector: Healthcare
• Industry: Medical Care Facilities

About: Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.

Employees: 112,035

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

137% more call options, than puts

Call options by funds: $3.06M | Put options by funds: $1.29M

88% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 16

23% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 52

13% more capital invested

Capital invested by funds: $770M [Q4 2024] → $873M (+$103M) [Q1 2025]

5% more funds holding

Funds holding: 188 [Q4 2024] → 198 (+10) [Q1 2025]

0.35% more ownership

Funds ownership: 11.59% [Q4 2024] → 11.94% (+0.35%) [Q1 2025]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $30 16% upside
• Avg. target: $30 16% upside
• High target: $30 16% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

Truist Securities David Macdonald

16% upside $30

Hold Maintained

12 May 2025